The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place May 31–June 4 in Chicago, drew more than 32,000 oncology specialists from around the world.
Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.
Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.
Cancer Network spoke with Anna Pavlick, MD, of NYU's Perlmutter Cancer Center, regarding whether there is one correct answer to front-line therapy for the treatment of advanced melanoma.
Cancer Network spoke with Hussein Abdul-Hassan Tawbi, MD, PhD, on the results of a phase II study of oral azacitidine in combination with pembrolizumab in metastatic melanoma.
Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan-Kettering Cancer Center about strategies and research surrounding optimized targeted therapy in melanoma.
Cancer Network spoke with Allison Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, about long-term outcomes and responses to retreatment in patients with melanoma receiving anti-PD1 therapy.
Dr. Karen L. Reckamp on Germline Mutations and Onset of Lung Adenocarcinoma in Smokers and Nonsmokers
Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope, about the link between several gene mutations and lung cancer in smokers vs nonsmokers.
Cancer Network spoke with Anna F.
Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma
Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.